AAAAAA

   
Results: 1-19 |
Results: 19
A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide
Authors: Huitema, ADR Mathot, RAA Tibben, MM Rodenhuis, S Beijnen, JH
Citation: Adr. Huitema et al., A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide, J PHARMA PH, 28(3), 2001, pp. 211-230
Sensitive gas chromatographic determination of the cyclophosphamide metabolite 2-dechloroethylcyclophosphamide in human plasma
Authors: Huitema, ADR Reinders, C Tibben, MM Rodenhuis, S Beijnen, JH
Citation: Adr. Huitema et al., Sensitive gas chromatographic determination of the cyclophosphamide metabolite 2-dechloroethylcyclophosphamide in human plasma, J CHROMAT B, 757(2), 2001, pp. 349-357
Urinary excretion of thioTEPA and its metabolites in patients treated withhigh-dose cyclophosphamide, thioTEPA and carboplatin
Authors: van Maanen, MJ Huitema, ADR Rodenhuis, S Beijnen, JH
Citation: Mj. Van Maanen et al., Urinary excretion of thioTEPA and its metabolites in patients treated withhigh-dose cyclophosphamide, thioTEPA and carboplatin, ANTI-CANC D, 12(6), 2001, pp. 519-524
Population pharmacokinetics of ifosfamide and its 2-and 3-dechloroethylated and 4-hydroxylated metabolites in resistant small-cell lung cancer patients
Authors: Kerbusch, T vanPutten, JWG Groen, HJM Huitema, ADR Mathot, RAA Beijnen, JH
Citation: T. Kerbusch et al., Population pharmacokinetics of ifosfamide and its 2-and 3-dechloroethylated and 4-hydroxylated metabolites in resistant small-cell lung cancer patients, CANC CHEMOT, 48(1), 2001, pp. 53-61
Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy
Authors: Huitema, ADR Mathot, RAA Tibben, MM Schellens, JHM Rodenhuis, S Beijnen, JH
Citation: Adr. Huitema et al., Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy, BR J CL PH, 51(1), 2001, pp. 61-70
Validation of a therapeutic drug monitoring strategy for thiotepa in a high-dose chemotherapy regimen
Authors: Huitema, ADR Mathot, RAA Tibben, MM Rodenhuis, S Beijnen, JH
Citation: Adr. Huitema et al., Validation of a therapeutic drug monitoring strategy for thiotepa in a high-dose chemotherapy regimen, THER DRUG M, 23(6), 2001, pp. 650-657
Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin
Authors: Kerbusch, T Jansen, RLH Mathot, RAA Huitema, ADR Jansen, M van Rijswijk, REN Beijnen, JH
Citation: T. Kerbusch et al., Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin, CLIN PHARM, 70(2), 2001, pp. 132-141
High-dose chemotherapy with peripheral blood progenitor cell transplantation in the adjuvant treatment of breast cancer
Authors: Rodenhuis, S Huitema, ADR van Dam, FSAM de Vries, EGE Beijnen, JH
Citation: S. Rodenhuis et al., High-dose chemotherapy with peripheral blood progenitor cell transplantation in the adjuvant treatment of breast cancer, CANCER J, 6, 2000, pp. S125-S130
Simple and selective determination of the cyclophosphamide metabolite phosphoramide mustard in human plasma using high-performance liquid chromatography
Authors: Huitema, ADR Tibben, MM Kerbusch, T Kettenes-van den Bosch, JJ Rodenhuis, S Beijnen, JH
Citation: Adr. Huitema et al., Simple and selective determination of the cyclophosphamide metabolite phosphoramide mustard in human plasma using high-performance liquid chromatography, J CHROMAT B, 745(2), 2000, pp. 345-355
Simultaneous determination of ifosfamide and its metabolite ifosforamide mustard in human plasma by high performance liquid chromatography
Authors: Kerbusch, T Huitema, ADR Jeuken, MJJ Derraz, J Tibben, MM Beijnen, JH
Citation: T. Kerbusch et al., Simultaneous determination of ifosfamide and its metabolite ifosforamide mustard in human plasma by high performance liquid chromatography, J LIQ CHR R, 23(19), 2000, pp. 2991-3010
High performance liquid chromatographic determination of the stabilized cyclophosphamide metabolite 4-hydroxycyclophosphamide in plasma and red bloodcells
Authors: Huitema, ADR Tibben, MM Kerbusch, T Kettenes-van den Bosch, JJ Rodenhuis, S Beijnen, JH
Citation: Adr. Huitema et al., High performance liquid chromatographic determination of the stabilized cyclophosphamide metabolite 4-hydroxycyclophosphamide in plasma and red bloodcells, J LIQ CHR R, 23(11), 2000, pp. 1725-1744
The clinical pharmacology of alkylating agents in high-dose chemotherapy
Authors: Huitema, ADR Smits, KD Mathot, RAA Schellans, JHM Rodenhuis, S Beijnen, JH
Citation: Adr. Huitema et al., The clinical pharmacology of alkylating agents in high-dose chemotherapy, ANTI-CANC D, 11(7), 2000, pp. 515-533
Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens
Authors: Huitema, ADR Kerbusch, T Tibben, MM Rodenhuis, S Beijnen, JH
Citation: Adr. Huitema et al., Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens, CANC CHEMOT, 46(2), 2000, pp. 119-127
Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM
Authors: Kerbusch, T Huitema, ADR Ouwerkerk, J Keizer, HJ Mathot, RAA Schellens, JHM Beijnen, JH
Citation: T. Kerbusch et al., Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM, BR J CL PH, 49(6), 2000, pp. 555-561
Influence of co-medicated drugs on the biotransformation of thioTEPA to TEPA and thioTEPA-mercapturate
Authors: van Maanen, MJ Huitema, ADR Beijen, JH
Citation: Mj. Van Maanen et al., Influence of co-medicated drugs on the biotransformation of thioTEPA to TEPA and thioTEPA-mercapturate, ANTICANC R, 20(3A), 2000, pp. 1711-1716
Determination of ifosfamide, 2-and 3-dechloroethyifosfamide using gas chromatography with nitrogen-phosphorus or mass spectrometry detection
Authors: Kerbusch, T Jeuken, MJ Derraz, J van Putten, JWG Huitema, ADR Beijnen, JH
Citation: T. Kerbusch et al., Determination of ifosfamide, 2-and 3-dechloroethyifosfamide using gas chromatography with nitrogen-phosphorus or mass spectrometry detection, THER DRUG M, 22(5), 2000, pp. 613-620
Validation of techniques for the prediction of carboplatin exposure: Application of Bayesian methods
Authors: Huitema, ADR Mathot, RAA Tibben, MM Schellens, JHM Rodenhuis, S Beijnen, JH
Citation: Adr. Huitema et al., Validation of techniques for the prediction of carboplatin exposure: Application of Bayesian methods, CLIN PHARM, 67(6), 2000, pp. 621-630
Sampling technique from central venous catheters proves critical for pharmacokinetic studies
Authors: Huitema, ADR Holtkamp, M Tibben, MM Rodenhuis, S Beijnen, JH
Citation: Adr. Huitema et al., Sampling technique from central venous catheters proves critical for pharmacokinetic studies, THER DRUG M, 21(1), 1999, pp. 102-104
Determination of N,N ',N ''-triethylenethiophosphoramide and its active metabolite N,N ',N ''-triethylenephosphoramide in plasma and urine using capillary gas chromatography
Authors: van Maanen, RJ van Ooijen, RD Zwikker, JW Huitema, ADR Rodenhuis, S Beijnen, JH
Citation: Rj. Van Maanen et al., Determination of N,N ',N ''-triethylenethiophosphoramide and its active metabolite N,N ',N ''-triethylenephosphoramide in plasma and urine using capillary gas chromatography, J CHROMAT B, 719(1-2), 1998, pp. 103-112
Risultati: 1-19 |